Liquidia Balance Sheet Health
Financial Health criteria checks 5/6
Liquidia has a total shareholder equity of $195.1M and total debt of $176.1M, which brings its debt-to-equity ratio to 90.3%. Its total assets and total liabilities are $521.9M and $326.8M respectively. Liquidia's EBIT is $168.6M making its interest coverage ratio 8.8. It has cash and short-term investments of $284.2M.
Key information
90.26%
Debt to equity ratio
US$176.11m
Debt
| Interest coverage ratio | 8.8x |
| Cash | US$284.18m |
| Equity | US$195.11m |
| Total liabilities | US$326.80m |
| Total assets | US$521.92m |
Recent financial health updates
Recent updates
LQDA: Legal Decisions Around Key Patents Will Drive Future Upside Potential
Analysts have lifted their fair value estimate for Liquidia from $72.38 to $107.75, citing stronger Yutrepia traction, higher long term earnings potential, and added upside optionality from L606 as key drivers behind the higher price targets across recent research updates. Analyst Commentary Recent Street research on Liquidia shows a mix of optimism around Yutrepia's commercial traction and longer term earnings potential, alongside caution on valuation and ongoing patent litigation.Liquidia: A Linear Launch Priced For Exponential Growth
Summary Liquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ valuation. YUTREPIA's percentage growth is compressing, prescriber acquisition has halved, and launch-era tailwinds are fading. Future growth will require difficult community penetration and overcoming structural headwinds from patient mortality and discontinuation. TPIP from Insmed poses a material long-term threat to LQDA's franchise, challenging assumptions of durable growth. Read the full article on Seeking Alpha
LQDA: Patent Rulings Will Shape Future Pulmonary Hypertension Earnings Power
Analysts have raised the fair value estimate for Liquidia stock from $60 to $90, citing higher Street price targets driven by strong Yutrepia uptake, growing market share, and additional long term optionality from L606, alongside ongoing legal and earnings considerations. Analyst Commentary Recent Street research on Liquidia points to a mixed but generally constructive tone.
LQDA: Future Patent Decisions Seen Driving Upside As Sentiment Turns More Positive
Analysts have lifted their fair value estimate for Liquidia stock from $102.99 to $130.00, reflecting updated assumptions on litigation outcomes around YUTREPIA and views that the drug could play a central role in treating PAH and PH-ILD if current legal and intellectual property questions are resolved in the company's favor. Analyst Commentary Recent Street research on Liquidia highlights a mix of optimism and caution that centers on litigation milestones, the commercial trajectory of YUTREPIA, and how these factors could influence the stock's valuation over time.LQDA: Pending Patent Outcomes Will Drive Future Earnings Upside Or Downside
Analysts lifted their fair value estimate for Liquidia to $60.00 from $16.99, citing higher Street price targets, stronger conviction in Yutrepia's potential positioning in PAH and PH-ILD, and updated assumptions around earnings power and legal outcomes. These changes are reflected in revised discount rate, margin, and future P/E inputs.LQDA: Legal Outcomes Around Key Patent Will Drive Future Upside
Analysts have lifted their implied fair value estimate for Liquidia from about $67.00 to roughly $103.00, citing updated models that reflect stronger expectations for Yutrepia, higher peak sales assumptions up to $2.2b, and legal outcomes that they view as better framed after recent court decisions. Some now prefer to wait for more clarity on key patent litigation before assuming further upside.LQDA: Legal Outcomes And Earnings Power Will Shape The Next Phase
Analysts have lifted the updated fair value estimate for Liquidia to $72.38 from $44.00, as higher assumed profit margins, a lower future P/E multiple, and evolving views on legal and earnings risk reshape their price target frameworks. Analyst Commentary Recent Street research on Liquidia highlights a mix of enthusiasm around potential earnings power and caution around legal outcomes, which together shape how analysts think about valuation and execution risk.Liquidia (LQDA) Stock Could Be 63.2% Overvalued After PHA 2026 YUTREPIA Update
Liquidia (LQDA) is back in focus after the company outlined four new poster presentations at the PHA 2026 International PH Conference, spotlighting fresh YUTREPIA data and broader pulmonary hypertension care insights. See our latest analysis for Liquidia. The PHA 2026 conference update comes at a time when Liquidia’s momentum has been strong, with a 30 day share price return of 26.12% and a 5 year total shareholder return of 2,737.94%. Together, these figures point to sentiment that has...Upgrade: Analysts Just Made A Captivating Increase To Their Liquidia Corporation (NASDAQ:LQDA) Forecasts
Shareholders in Liquidia Corporation ( NASDAQ:LQDA ) may be thrilled to learn that the analysts have just delivered a...Liquidia Corporation (NASDAQ:LQDA) Looks Just Right With A 30% Price Jump
Liquidia Corporation ( NASDAQ:LQDA ) shares have had a really impressive month, gaining 30% after a shaky period...Liquidia Corporation's Long-Running Saga Is Coming To An End
Summary Today, we are circling back on Liquidia Corporation, as its long-running litigation battle with United Therapeutics is finally coming to a positive end. This means we will likely see the full commercial launch of its primary candidate, YUTREPIA before the end of the second market. YUTREPIA is targeting a large potential market and could garner significant market share. An updated analysis around Liquidia Corporation follows in the paragraphs below. Read the full article on Seeking AlphaFinancial Position Analysis
Short Term Liabilities: LQDA's short term assets ($437.7M) exceed its short term liabilities ($189.3M).
Long Term Liabilities: LQDA's short term assets ($437.7M) exceed its long term liabilities ($137.5M).
Debt to Equity History and Analysis
Debt Level: LQDA has more cash than its total debt.
Reducing Debt: LQDA's debt to equity ratio has increased from 13% to 90.3% over the past 5 years.
Debt Coverage: LQDA's debt is well covered by operating cash flow (95.2%).
Interest Coverage: LQDA's interest payments on its debt are well covered by EBIT (8.8x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 12:41 |
| End of Day Share Price | 2026/09/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Liquidia Corporation is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Julian Harrison | BTIG |
| Andrew Fein | H.C. Wainwright & Co. |